Physician profile
Glenn Corbin
NPI 1508828666
$46,623.54
in general payments reported to CMS, 2019-2025
30 companies · $963 in 2025
The $963 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $9,619 · 2021: $18K · 2022: $1,815 · 2023: $869 · 2024: $1,265 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,097.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Maculogix, INC. | $36,221.73 | 2019-2021 | |
| Alcon Vision LLC | $4,078.00 | 2019-2025 | Total30, Precision 1, Dailies Total1 |
| Coopervision INC. | $1,078.09 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens |
| Notal Vision, INC. | $699.68 | 2022 | |
| Allergan, INC. | $507.99 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $450.87 | 2023-2025 | Xiidra, Miebo, Infuse |
| Sun Pharmaceutical Industries INC. | $367.08 | 2019-2025 | Cequa |
| Lkc Technologies, INC. | $344.82 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $284.43 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $275.80 | 2019-2021 | |
| Shire North American Group INC | $232.00 | 2019 | |
| Oyster Point Pharma, INC. | $218.50 | 2022-2024 | Tyrvaya |
| Rxsight INC | $206.79 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Dompe US, INC. | $176.90 | 2023-2025 | Oxervate |
| Glaukos Corporation | $155.97 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $151.09 | 2022-2023 | Lumigan, Vuity |
| Novartis Pharmaceuticals Corporation | $150.77 | 2020-2022 | |
| Astellas Pharma Global Development | $150.00 | 2024 | Izervay |
| Horizon Therapeutics Plc | $142.83 | 2021-2022 | |
| Biotissue Holdings INC. | $119.24 | 2020-2025 | |
| Alcon Research LLC | $111.16 | 2019 | |
| Apellis Pharmaceuticals, INC. | $109.99 | 2024 | Syfovre |
| Ortho-Clinical Diagnostics, INC. | $101.11 | 2024 | Inflammadry |
| Johnson & Johnson Vision Care, INC. | $84.00 | 2019-2023 | Acuvue |
| Quidel Corporation | $57.31 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $57.08 | 2021 | |
| Abb Con-Cise Optical Group LLC | $35.26 | 2019 | |
| Astellas Pharma US INC | $34.96 | 2024 | Izervay |
| Harrow Eye, LLC | $20.09 | 2025 | Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.